Tirbanibulin

N/A

Report date: 2026/05/23 20:00:57
NMEFirst In Class

Base Information

Drug NameTirbanibulin
Drug Alias NameKLISYRIKlisyriKX2-391KX-2391KXO-1 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsTyrosine-protein kinase SRC inhibitors
TargetsTubulinTyrosine-protein kinase SRC
Therapy Area/IndicationsSolid tumoursObesityInsulin Resistance +[14] 
Global Approved IndicationsKeratosis, Actinic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/12/14
Country/TerritoryUnited StatesPolandNetherlands +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAthenex Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlmirall SasChongqing Jingdong Junzhuo Pharmaceutical Co LtdSagard Healthcare Partners +[11] 
Inactive CompaniesHanmi Pharmaceutical Co LtdRoswell Park Cancer InstituteKinex Pharmaceuticals Inc
Active IndicationsObesityInsulin ResistanceKeratosis +[5] 
Inactive IndicationsSolid tumoursPsoriasisLymphoproliferative Disorders +[9] 

Other Information

ATC CodeD06BX
Related LinksWikipediaDrugBankKEGG